Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (Nasdaq: FULC) announced the granting of stock options for 6,180 shares to a new employee as inducement awards under its 2022 Inducement Stock Incentive Plan. The options, issued on October 3, 2022, have an exercise price of $8.16 per share, equal to the closing stock price on that date. These options will vest over four years, with a quarter vesting after the first year and the remainder in quarterly installments. Fulcrum focuses on developing treatments for genetically defined rare diseases with significant unmet medical needs.

Fulcrum Therapeutics (NASDAQ: FULC) announced the granting of 59,500 non-statutory stock options to three new employees on September 6, 2022. These options serve as inducement awards outside the 2019 Stock Incentive Plan. The exercise price is set at $7.47 per share, corresponding to the closing price on the grant date. Each option has a ten-year term with a four-year vesting period, allowing 25% to vest after the first year and the remainder in quarterly installments. Fulcrum focuses on developing treatments for genetically defined rare diseases.

Fulcrum Therapeutics (Nasdaq: FULC) is set to participate in key investor conferences, including the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, and the Morgan Stanley 20th Annual Global Healthcare Conference, which will feature a fireside chat on September 14, 2022, at 10:00 a.m. ET. The Morgan Stanley chat will be available live via the Fulcrum Investor Relations website, with a recording accessible for 30 days afterward. Fulcrum focuses on rare genetic diseases and has two lead programs in development: losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced participation in a fireside chat at the Stifel 2022 Biotech Summer Summit on August 17, 2022, at 11:30 a.m. ET. The company focuses on developing treatments for genetically defined rare diseases, with lead programs including losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 targeting sickle cell disease. Fulcrum's proprietary platform, FulcrumSeek™, aims to address gene expression issues to tackle the root causes of these diseases. For more details, visit www.fulcrumtx.com.

Fulcrum Therapeutics (Nasdaq: FULC) announced a public offering of 9,590,792 shares of common stock at $7.82 per share, aiming to raise $75 million before expenses. The offering is led by Goldman Sachs and SVB Securities, with a 30-day option for underwriters to purchase an additional 1,438,618 shares. The closing date is projected for August 18, 2022. The shares are offered under an effective shelf registration statement with the SEC, ensuring compliance for the transaction. This move supports Fulcrum's focus on developing therapies for rare genetic diseases.

Fulcrum Therapeutics (Nasdaq: FULC) announced an underwritten public offering of $75 million in common stock, with an additional $11.3 million option for underwriters. Led by Goldman Sachs & Co. LLC and SVB Securities, the offering is subject to market conditions and may not guarantee completion. Shares will be offered under an effective shelf registration statement filed with the SEC, and a preliminary prospectus supplement will be available at SEC’s website. The funds will support Fulcrum’s clinical programs targeting rare diseases, including FSHD and sickle cell disease.

NextRNA Therapeutics announces the appointment of Dominique Verhelle, PhD, MBA, as CEO, effective immediately. Verhelle, a co-founder of the company, has spearheaded its scientific and corporate strategy since its inception. Under her leadership, NextRNA secured $56M in financing to advance its unique platform aimed at developing small molecule drugs targeting non-coding RNA interactions. Additionally, Jason Katz has been appointed as VP and Head of Drug Discovery, bringing extensive drug discovery experience from IFM Therapeutics and Merck.

Fulcrum Therapeutics (FULC) reported key advancements in clinical trials and a strategic realignment to enhance operational efficiency. Initial data from the Phase 1b trial of FTX-6058 in sickle cell disease showed promising increases in hemoglobin F (HbF), while the Phase 3 REACH trial for losmapimod in facioscapulohumeral muscular dystrophy has begun enrolling patients. The company plans to cut operating expenses by $40-50 million and extend its cash runway into mid-2024. As of June 30, 2022, cash and equivalents totaled $169 million, down from $218 million at the end of 2021.

Fulcrum Therapeutics, Inc. (Nasdaq: FULC) will release its second quarter 2022 financial results on August 11, 2022, before the U.S. markets open. The company, focused on treating genetically defined rare diseases, will host a conference call at 8:00 a.m. ET for discussions regarding the results and recent developments. Key programs include losmapimod for facioscapulohumeral muscular dystrophy and FTX-6058 for sickle cell disease. A webcast will also be available for those unable to join live.